Cardiff Oncology reports positive phase 2 trial results for cancer drug

June 2, 2026 9:06 AM

Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found